Aticaprant (CERC-501, LY-2456302) is a potent, orally bioavailable, centrally-penetrant antagonist of the kappa opioid receptor with a Ki of 0.807 nM. It exhibits an antidepressant effect with the potential to treat major depressive disorder (MDD).

Aticaprant (CERC-501, LY-2456302) is a potent, orally bioavailable, centrally-penetrant antagonist of the kappa opioid receptor with a Ki of 0.807 nM. It exhibits an antidepressant effect with the potential to treat major depressive disorder (MDD).

Aticaprant (CERC-501, LY-2456302) is a potent, orally bioavailable, centrally-penetrant antagonist of the kappa opioid receptor with a Ki of 0.807 nM. It exhibits an antidepressant effect with the potential to treat major depressive disorder (MDD).

Aticaprant (CERC-501, LY-2456302) is a potent, orally bioavailable, centrally-penetrant antagonist of the kappa opioid receptor with a Ki of 0.807 nM. It exhibits an antidepressant effect with the potential to treat major depressive disorder (MDD).

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research.

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).